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Abstract
Background: Inflammatory airway disease (IAD) in horses, similar to asthma in humans, is a common cause of
chronic poor respiratory health and exercise intolerance due to airway inflammation and exaggerated airway
constrictive responses. Human rhinovirus is an important trigger for the development of asthma; a similar role for
viral respiratory disease in equine IAD has not been established yet.
Methods: In a case–control study, horses with IAD (n = 24) were compared to control animals from comparable
stabling environments (n = 14). Horses were classified using pulmonary function testing and bronchoalveolar lavage.
PCR for equine rhinitis virus A and B (ERAV, ERBV), influenza virus (EIV), and herpesviruses 2, 4, and 5 (EHV-2, EHV-4,
EHV-5) was performed on nasal swab, buffy coat from whole blood, and cells from BAL fluid (BALF), and serology
were performed. Categorical variables were compared between IAD and control using Fisher’s exact test; continuous
variables were compared with an independent t-test. For all analyses, a value of P <0.05 was considered significant.
Results: There was a significant association between diagnosis of IAD and history of cough (P = 0.001) and exercise
intolerance (P = 0.003) but not between nasal discharge and IAD. Horses with IAD were significantly more likely to have
a positive titer to ERAV (68 %) vs. control horses (32 %). Horses with IAD had higher log-transformed titers to ERAV than
did controls (2.28 ± 0.18 v.1.50 ± 0.25, P = 0.038). There was a significant association between nasal shedding (positive
PCR) of EHV-2 and diagnosis of IAD (P = 0.002).
Conclusions: IAD remains a persistent problem in the equine population and has strong similarities to the human
disease, asthma, for which viral infection is an important trigger. The association between viral respiratory infection and
development or exacerbation of IAD in this study suggests that viral infection may contribute to IAD susceptibility;
there is, therefore, merit in further investigation into the relationship between respiratory virus exposure and
development of IAD.
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Background
Inflammatory airway disease (IAD) has been identified
as a common cause of respiratory abnormalities and
poor performance in horses. IAD is characterized by air-
way inflammation and airway hyperresponsiveness [1] as
well as exercise intolerance, variable coughing, nasal dis-
charge, and increased mucus in the airways [2], and
affects a large percentage of stabled horses, resulting in
chronic poor respiratory health and poor performance
[3–5]. The pathophysiology of IAD has not been fully
elucidated and is thought to be influenced by both envir-
onmental and genetic factors [6]. Although exposure to
environmental particulates and endotoxin likely plays a
large role in the induction of IAD [7], a role for viral in-
fection in lower airway inflammation has been proposed
[5]. Humans suffer from a similar disease, asthma, and
respiratory viruses have been firmly connected to the
induction and exacerbation of asthma [8]. Human
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rhinovirus (HRV), genus enteroviridae of the family
picornaviridae, is the predominant cause of the com-
mon cold and is the most common viral cause of ex-
acerbation of wheezing in patients with asthma [9].
Equine rhinitis virus (ERV, until recently classified as
a rhinovirus), is also a picornavirus with the A variant
(ERAV) in the Apthovirus genus and the B variants
(ERBV-1,2,3) in the Erbovirus genus [10], and is similarly
a common cause of respiratory infection in horses [11].
The incidence of ERV in certain equine populations is
high, with 43 % of Australian racehorses seroconverting to
ERAV within 7 months of entering a training barn [10],
however, a role for equine rhinitis viruses in poor per-
formance has yet to be proved [12].
Herpesviruses have also been implicated in poor per-
formance in horses: past studies have associated equine
herpesvirus-1 (EHV-1) and equine herpesvirus-4 (EHV-4)
infection with IAD, but they have only employed serology
[13]. More recently, naturally occurring equine
herpesvirus-2 (EHV-2) infection confirmed by PCR has
been associated with increased numbers of neutrophils in
the respiratory secretions [14] and inoculation with EHV-
2 has been shown to result in prolonged (3-week) airway
inflammation [15]. Our current study evaluates horses
which fulfill a case definition of recent onset or exacerba-
tion of IAD (within the past month) versus control horses
for evidence of exposure or active infection with common
respiratory viruses including ERAV, ERBV, EHV-2, EHV-4,
equine herpesvirus-5 (EHV-5), and equine influenza virus
(EIV) measured by PCR of bronchoalveolar lavage fluid
cell pellets, peripheral blood buffy coat, and nasal swab,
and by serologic detection of viral antibodies. We hypoth-
esized that recent infection with equine rhinitis viruses or
other respiratory viruses, similar to respiratory viruses and
asthma, is associated with exacerbation or induction of
equine IAD.
Methods
In accordance with the Consensus on IAD by the Ameri-
can College of Veterinary Internal Medicine [6], criteria
for horses with IAD included a history compatible with
non-infectious inflammatory airway disease, including
cough, exercise intolerance/poor performance, or nasal
discharge, as well as recent (within 4 weeks) onset or ex-
acerbation of signs. Further inclusion criteria upon diag-
nostic sampling included inflammatory BALF cytology
(PMNs > 5 % OR mast cells > 2 % OR both). Exclusion cri-
teria for IAD horses included a history more suggestive of
recurrent airway obstruction (RAO), including obvi-
ous respiratory effort at rest and repeatable episodes
of respiratory difficulty when exposed to dusty or
moldy environments, recent fever (within 4 weeks), or
evidence of bacterial infection on BALF cytology.
Control horses were included only if they did not
present any history or evidence on physical examin-
ation of respiratory disease including cough, nasal dis-
charge, or respiratory effort, or fever for any reason
within the past 4 weeks. Control horses were also required
to have normal BALF cytology and no evidence of airway
hyperresponsiveness or airway obstruction. Horses for this
study included those presented to the Hospital for Large
Animals at the Cummings School of Veterinary Medicine
at Tufts University as well as those seen in the field. In
order to standardize environmental conditions, horses
were only included in the study if they were stabled at
night and turned out during the day, and were fed a com-
bination of hay and concentrate. Horses came from barns
with a minimum of 2 horses and a maximum of 30 horses.
One barn provided 4 horses, 2 of which had IAD and 2 of
which were controls. One barn provided 3 controls, and
one barn provided 2 controls. All other horses, both IAD
and control, were from separate barns. Both IAD and con-
trol horses were sampled throughout the year at similar
frequencies, although more IAD than control horses were
sampled at all times of year. All horses were pleasure
horses or lower-level sport horses. We sampled 46 horses,
including 26 horses with a history compatible with IAD
and 18 horses without an owner or referring veterinarian
complaint of suspected respiratory disease. Of the horses
with suspected IAD, 2 had a history or signs on physical
examination or lung function testing that were compatible
with RAO; these horses were excluded but the other 24
were included in this study. Out of the 18 potential con-
trol horses, 3 were lost due to positive histamine broncho-
provocation tests, and one due to presence of guttural
pouch infection.
Testing overview
Horses first underwent physical examination including
use of a rebreathing bag to enhance auscultation; subse-
quently, baseline lung function testing and histamine
bronchoprovocation (HBP) testing or albuterol challenge
were performed followed by bronchoalveolar lavage. Pul-
monary function testing required from 20 to 45 min de-
pending on the method used and airway responsiveness
of the horse (e.g., forced oscillatory mechanics (FOM) is
performed more quickly than flowmetric plethysmogra-
phy (FP, Open Pleth), and histamine bronchoprovocation
is truncated in horses with more reactive airways regard-
less of method used.) Horses with total respiratory sys-
tem resistance (RRS) > 1.5 cmH2O/l/s were given 5 puffs
of albuterol1 via Aerohippus2 [16] and lung function was
re-measured after 20 min. A positive response was con-
sidered a 25 % or greater decrease in RRS. After lung
function testing, bronchoalveolar lavage, nasal swab, and
blood draw were performed as described below, taking
in total approximately 30 min. The entire procedure
took from 1–1.5 h for each horse.
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Bronchoalveolar lavage and slide preparation
BAL was performed with either a commercial cuffed
BAL tube3 or by bronchoscopy, and 2 aliquots of 250 ml
warmed saline, as described previously [1]. The 2 sam-
ples were pooled, and slides were prepared by cytocen-
trifugation or by centrifugation followed by making a
thin smear with the sediment. In addition, the BAL fluid
was kept on ice and processed within 4 hours for PCR
identification of selected viruses. BAL slides were stained
with modified Wright stain and Toluidine Blue4, the lat-
ter for enumeration of mast cells [17]. Cells were classi-
fied by one of the authors (MRM) as percentage of
macrophages, lymphocytes, neutrophils (PMN), eosino-
phils, and mast cells by classifying a minimum of 500
cells (1,000× magnification).
Pulmonary function testing
Each horse underwent baseline pulmonary function test-
ing followed by either histamine bronchoprovocation or
albuterol challenge using either flowmetric plethysmog-
raphy or forced oscillatory mechanics.
Flowmetric plethysmography was performed with a
commercial system5 as described previously [16]. Briefly,
each horse was sedated (detomidine6 0.01-0.02 mg/kg
BW IV), and fitted with an airtight mask, pneumotacho-
graph7, and 2 respiratory inductance bands placed at the
11th intercostal space and just behind the last rib. The
system was calibrated according to the manufacturer’s
instructions. Measurement of airway obstruction was
calculated by the software by subtracting the flow signal
generated by the thoracic and abdominal volume change
from the air flow measured by the pneumotachograph at
peak expiration, termed the delta flow (DF). Delta flow
increases with bronchoconstriction, as the expected airflow
through the pneumotachograph is less than the observed
volume shift over time as measured by the abdominal and
thoracic bands.
Monosinusoidal forced oscillatory mechanics (FOM, 1-
3Hz) was performed as previously described [18]. In brief,
total respiratory system resistance (RRS) was measured in
sedated horses (0.4–0.6 mg/kg BW xylazine8 IV). Sinus-
oidal flow (1–3 Hz) was generated using compressed air
(75 psi) released through a proportional pneumatic valve9
and superimposed over the horse’s spontaneous breathing
frequency via a latex sealed low dead space facemask. Flow
at the mask opening was measured with a pneumotacho-
graph and the difference between mask and atmospheric
pressures was recorded with a differential pressure trans-
ducer10. Total respiratory impedance and resultant respira-
tory resistance were calculated as described previously [18].
Histamine bronchoprovocation
Airway hyperresponsiveness was assessed via histamine
bronchoprovocation as previously described [2]. In
short, after baseline measurements, either total RRS or
DF were measured after nebulization with 0.9 % saline11
(as negative control), and incremental concentrations of
histamine12 (2,4,8,16 ,and 32 mg/ml). Sensitivity to hista-
mine was determined as the dose (mg/ml) required to
elicit a 75 % increase in RRS using FOM or a 50 % in-
crease in DF using flowmetric plethysmography by
interpolation of the dose–response curve [19, 20]. For
either method, testing was halted if clinical reaction (in-
creased respiratory rate or effort, repeated coughing)
was detected in the horse and the histamine dose at
which the clinical reaction occurred was considered to
be the reactive dose.
Albuterol challenge
In horses with baseline RRS > 1.5 cmH2O/l/s (3 animals),
albuterol was given via metered dose inhaler using the
Aerohippus (5 puffs, 90 ucg/puff ) to elicit bronchodila-
tion. A positive response was considered ≥ 25 % decrease
in RRS. No horse tested via flowmetric plethysmography




Collection tubes of whole blood were allowed to clot for
30 min after sampling, and were centrifuged at 3,000 × g
for 10 min at 4 C. The serum was separated and stored
at −80 °C until submission for serologic testing.
PCR
All samples were kept on ice until they were processed.
Four collection tubes of BALF were centrifuged at 500xg
for 10 min at 4 °C. Cell pellets were isolated and stored
in RNAprotect13, and the nasal swab was placed in viral
culture medium14. Blood in EDTA was centrifuged at
3,000 × g for 10 min at 4 °C, and the buffy coat was re-
moved and stored in RNAprotect. All samples were held
at −80 °C until submission for PCR.
Nucleic acid extraction from whole blood, nasal secre-
tions and bronchoalveolar lavage fluid was performed
using an automated nucleic acid extraction system15 ac-
cording to the manufacturer’s recommendations.
Total RNA was purified as follows: 20 ul of each
freshly extracted nucleic acid sample containing genomic
DNA (gDNA) and total RNA was digested with DNAse
for 60 min at follows: 20 ul of each freshly extracted nu-
cleic acid sample (containing genomic DNA (gDNA)
and total RNA) was digested with DNAse for 60 min at
37 °C to remove gDNA. DNase was inactivated at 95 °C
for 5 min. Complementary DNA (cDNA) from each
sample was synthesized using 50 U SuperScript III16 in a
40 ul final volume containing 50 mM Tris–HCl, pH 8.3,
50 mM KCl, 8 mM MgCl2, 0.5 mM dNTPs, 40 U
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RNAsin, 0.5 mM dithiothreitol (DTT) and 600 ng
random hexadeoxyribonucleotide (pd(N)6) primers (ran-
dom hexamers17). The reaction was performed at 50 °C
for 60 min. After inactivation at 95 °C for 5 min, the re-
action volume was adjusted to 100 ul with nuclease-free
water. Whole blood, nasal secretions and bronchoalveo-
lar lavage fluid was assayed for the presence of EIV,
EHV-2, EHV-4, EHV-5, ERAV and ERBV using previ-
ously reported qPCR assays [21, 22]. To determine the
sample quality and efficiency of nucleic acid extraction
we analyzed all samples for the presence of the house-
keeping gene equine glyceraldehyde-3-phosphate de-
hydrogenase (eGAPDH), as previously described [23].
Serologic testing
Evidence of viral infection was assessed through sero-
logical examination of single blood samples by using
serum neutralization tests for EHV-2, EHV-4, ERAV-1,
and ERBV-2, and hemagglutination inhibition tests for
EIV-A. Because of inability to determine vaccinal vs in-
fectious cause of positive titers for EHV-4 and EIV-A
when only one time point was considered, we only ana-
lyzed serology for EHV-2, ERAV-1, and ERBV-2, none of
which had available vaccines at the time of the study.
Serologic testing was not performed for EHV-5. All sero-
logic testing was performed at Cornell Animal Health
Diagnostics Center. A positive titer was determined ac-
cording to guidelines from the Cornell Animal Health
Diagnostics Center (personal communication, Dr. Ed-
ward Dubovi), as follows: Titers considered consistent
with infection or exposure were defined as follows: ≥8
for EHV-2, ≥96 for ERAV, and ≥32 for ERBV.
Statistical analysis
All continuous variables were examined graphically for
normality. Non-normally distributed continuous vari-
ables are described with median (range), and normally
distributed continuous variables are described with
mean ± SEM. Continuous variables that were not nor-
mally distributed were transformed mathematically prior
to analysis, and described with mean ± SEM. Categorical
variables were compared between horses with and with-
out IAD using Fisher’s exact test. Continuous variables
were compared between horses with and without IAD
using independent t-test. For all analyses, a value of
P < 0.05 was considered significant. Data analyses were
performed using commercial statistical software18.
Results
A total of 24 horses with a diagnosis of IAD based on
the previously mentioned criteria, and 14 asymptomatic
control horses were included in the study. The mean age
of IAD-affected horses was 16.2 years ± 0.9, and the
mean age of the controls was 14.5 years, ± 1.9. Breeds
accounting for 15–23 % of horses were Quarterhorse
and Warmblood, breeds accounting for 10–13 % of
horses were Grade and Morgan, and Standardbred,
Draft, Thoroughbred, Appaloosa, and Paso Fino each
accounted for 5 % or less. There were no differences be-
tween the IAD and CTL populations for age, sex, or
breed (Table 1). Horses with evidence of airway inflam-
mation or abnormal lung function were excluded from
the control population; accordingly, IAD horses had sig-
nificantly greater numbers of neutrophils and mast cells
in the BALF, and PC75RRS/PC50DF were significantly
lower (Table 1). Only 5/24 IAD horses had elevated per-
centages of mast cells with normal percentages of neu-
trophils, 6/24 had elevated percentages of both mast
cells and neutrophils, and the remainder, 13/24, had only
elevated percentages of neutrophils. The majority of IAD
horses had both abnormal BALF cytology and abnormal
pulmonary function tests (21/24). The 3/24 IAD horses
with normal PFTs had normal PMN percentages on
BALF with elevated mast cell percentages. There was a
strong association between elevated percentages of
BALF neutrophils or mast cells and abnormal lung func-
tion (either airway hyperresponsiveness (AWHR) or re-
sponse to albuterol challenge), P < 0.001. The majority of
horses with IAD had an owner complaint of cough
(75 %), or exercise intolerance/poor performance (83 %),
whereas only a small number had an owner complaint
of nasal discharge (17 %). There was a significant associ-
ation between history of cough (P = 0.001) and exercise
intolerance (P = 0.003) and diagnosis of IAD, but not be-
tween nasal discharge and IAD (Table 1). There was no
association between history of cough or exercise intoler-
ance and PCR-detection of any virus.
Serology was available for 22/24 horses with IAD and
13/14 control horses. There was a high seroprevalence for
ERAV (54 %), ERBV (89 %), and EHV-2 (40 %) in the en-
tire population, but horses with IAD more frequently had
positive titers to ERAV (68 %) v. control horses
(31 %) (P < 0.03) (Table 2). Horses with a diagnosis of
IAD had higher log-transformed titers to ERAV than
did control horses. (2.28 ± 0.18 v. 1.50 ± 0.25, P = 0.038)
(Fig. 1).
PCR was available for all horses in the study. No
sample for any horse was positive for EHV-4 or
ERAV. Out of 38 horses tested, only 12 were PCR
positive on any sample for any virus, 9/12 of these
horses were in the IAD group. Six IAD horses were
positive for EHV-2 on nasal swab, but no control
horse was positive (Table 3). There was a significant
association between nasal shedding (positive PCR) of
EHV-2 and diagnosis of IAD (P = 0.002) (Table 3).
There were no associations between airway neutrophi-
lia or mastocytosis and positive PCR status or be-
tween AWHR and positive PCR status.
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Table 1 Descriptive statistics for the study population
Group Number Age Clinical signs
(total number, percent)










Control 14 14.5 ± 1.99 (5–26) 0 (0) 4 (29 %) 0 2.7 ± 1.6 (0–5) 0.5 ± 1.6 (0.0–1.8) 13.48 ± 1.17 (6.7–24.0) None
IAD 24 16.2 ± 0.9 (9–25) 18 (75 %) 20 (83 %) 4 (16.7 %) 22.5 ± 4.4 (0.0–85.0) 3.29 ± 0.7 (0.0–16.0) 5.25 ± 0.90 (0.5–16.9) 3
All horses had history, clinical examination, bronchoalveolar lavage, and baseline pulmonary function testing performed. The majority of horses had HBP performed; 3 horses with RRS > 1.5 cmH2O/l/s had albuterol
challenge performed with at least 25 % decrease in RRS. Cough, exercise intolerance/poor performance, and nasal discharge reflect the owner complaint. PMN and mast refer to the neutrophil and mast cell
percentages found on cytology of BALF. Histamine refers to the results of a histamine bronchoprovocation test using either FOM or Open Pleth. A lower number indicates greater reactivity of the airways. Albuterol
















This study was designed to determine if current or re-
cent infection with equine rhinitis virus or other respira-
tory viruses plays a role in the development or
worsening of IAD. In humans, wheezing episodes in
early life due to infection with HRV significantly increase
the chances of a diagnosis of the similar disease, asthma,
at six years of age [24], and infections later in life are as-
sociated with worsening of asthma [25]. Herpesviruses
are less firmly linked to wheezing episodes in early life
in human infants [25], but may be associated with devel-
opment of other atopic disease through immune dysreg-
ulation [26]. Despite the strong association of HRV with
asthma, recent data suggest that development of asthma
later in life may be dependent on the number of viral re-
spiratory infection episodes rather than the type of virus
[27]. In all, the evidence firmly inculpates respiratory
virus as an important determinant of development of
asthma. In contrast, although researchers and clinicians
have long suspected that respiratory viruses are import-
ant to the development or exacerbation of IAD in horses
[5, 28, 29], there is a paucity of data in the veterinary lit-
erature definitively making this link, and this lack was
identified in the last ACVIM Consensus Statement on
IAD [6].
Our study showed that there was a significant associ-
ation between diagnosis of IAD and seropositivity to
ERAV, with 68 % of horses with IAD versus 31 % of con-
trol horses having a titer ≥96 (Table 2). A vaccine for
ERAV has only recently been available commercially,
and was not available during the study time period; thus,
these titers reflect the natural infection status of the
horses. Not only did more IAD than CTL horses have
positive titers to ERAV, but IAD horses also had signifi-
cantly higher log-transformed titers for ERAV than did
control horses (Fig. 1). Although serology for EHV-2
failed to distinguish IAD from CTL horses (Table 2),
and few horses were PCR positive on any sample to
any virus (Table 3), nonetheless there was a significant
association between EHV-2 shedding (positive nasal
swab on PCR) and diagnosis of IAD (Table 3), primar-
ily because the only horses positive on nasal swab for
EHV2 had a diagnosis of IAD. Although these associa-
tions do not provide any causal relationships, they do
provide us some justification for further investigation
and discussion.
Table 3 Respiratory virus and sample site for horses positive on
PCR testing
Horse Disease status EHV-2 EHV-5 ERBV EIV
1 CTL NS, BAL
2 CTL BC BAL
3 CTL BAL
4 IAD NS NS
5 IAD NS
6 IAD BC NS
7 IAD NS NS, BAL, BC
8 IAD BC, NS
9 IAD BAL
10 IAD NS NS,BAL BAL
11 IAD NS BC
12 IAD BAL
This table only shows the horses that were positive on at least one sample
when PCR was used to test for presence of virus. PCR for ERAV and EHV-4 is
not shown as there were no positive samples on PCR. 12 horses had at least
one PCR positive sample. The table shows the individual horses who were
shedding EHV-2
BC buffy coat, BAL bronchoalveolar lavage cell pellet, NS nasal swab
Fig. 1 Serum neutralizing antibodies to ERAV were measured in
22/24 horses with a diagnosis of IAD and in 13/14 control horses.
The antibody titers were log-transformed and expressed as mean ±
standard error of the mean. Student’s paired t-test was used and
found that ERAV titers in the IAD group were significantly higher
than in the CTL group (2.28 ± 0.18 v. 1.50 ± 0.25). *Indicates a
significant difference between groups (P = 0.038)
Table 2 Seroprevalence for ERAV, ERBV, and EHV2 in the study
population
Exposure ERAV ERBV EHV2
IAD CTL IAD CTL IAD CTL
Positive 15 4 20 11 8 6
Negative 7 9 2 2 14 7
% Positive *68 31 91 85 36 46
Seroprevalence 54 89 40
Serology was performed on 22/24 horses in the IAD group, serum samples
were unavailable for 2 horses. Serology was performed in 13/14 horses in the
CTL group, serum samples were unavailable for 1 horse. Percent positive for
IAD and CTL groups are given for each virus ; seroprevalence for the
population as a whole is also given. Titers considered consistent with infection
or exposure were defined as follows: ≥8 for EHV-2, ≥96 for ERAV, and ≥32 for
ERBV *Horses with IAD were significantly more likely to have a positive titer
(>96) to ERAV (P < 0.03)
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In considering the serologic evidence for the role of
ERAV in the etiology of IAD, it is important to consider
what has previously been termed a positive titer and
used to report seroprevalences. Our study employed the
cut-point of 96 for ERAV using the guidelines of the la-
boratory in which the serological testing was performed
(Edward Dubovi, personal communication), and was con-
cordant with that used in a study in which seropositive
horses had titers of ≥100 [30]. In contrast, in other studies,
a positive serum-neutralizing titer has been considered >2
[31], and >10 [10] although it was noted that in older
horses titers were in the range of >512 . In a recent experi-
mental study, all ponies prior to infection had serum neu-
tralizing titers for ERAV <2, rising to 64 on day 7 after
infection [32] whereas in a suspected natural outbreak, ti-
ters of 1,024 were seen [33]. Although there is variability
in the designation of a positive titer, nonetheless, our cut-
point is within the range of those previously reported. In
addition, both age and geography seem to be important in
determining seroprevalence for ERAV, with titers lower in
younger horses and higher in older horses; as our horses
were not young, we would expect their titers to be in the
higher range [31]. In contrast, the majority of studies finds
that seroprevalence to ERBV is high in multiple age
groups [34], similar to our findings (Table 2).
There are varying reports of active disease based on
virus isolation and PCR for ERVs depending on the
methodology used, whereas there is a consensus that
HRV is ubiquitous in human populations [35]. Although
PCR is more sensitive than virus isolation, in a recent
study of over 200 cases of suspected naturally occurring
viral respiratory disease only 11 % of those that were
negative for ERAV on virus isolation were positive on
PCR [36]. Our study, in which no horse was PCR posi-
tive for ERAV and only 3/38 horses had nasal secretions
positive for ERBV (Table 3), was similar to one recently
reported in which no horses with acute respiratory dis-
ease had PCR-positive nasal swab, and ERBV was found
in the nasal secretions of only 2.7 % of horses [21]. A
year-long longitudinal study in young Standardbreds
likewise found a small number of horses PCR positive
for any respiratory virus on nasal swab [12]. Positive
PCR identification of the other respiratory viruses
(whether on BALF cell pellet, nasal swab, or buffy coat)
was found with relatively low frequency in our study
[Table 3]. This low prevalence of PCR positive results
likely reflects the variable natural course of disease.
Similarly to HRV in humans, ERAV is cleared quickly
from the equine respiratory system (within 2 weeks)
[11]. Despite this rapid clearance, high antibody titers
are still present at 21 to 35 days after infection with
ERAV [11, 33]. This is most likely the reason that, in
contrast to our expectation that PCR detection of virus
would be more effective in providing the link between
respiratory viral disease and diagnosis of IAD, instead,
due to sample timing, the indirect serologic evidence
was more revealing.
In addition to a possible role for rhinitis viruses, our
study showed that although only a small subset of horses
was positive on nasal swab for EHV-2, this nonetheless
was positively associated with a clinical diagnosis of
IAD. EHV-2 is a slow-growing cytomegalovirus that has
been reported to infect foals early in life and to have a
high seroprevalence [37]. Although the pathogenicity of
EHV-2 has previously been debated given that it can be
recovered from both clinically affected and healthy ani-
mals [13], studies have linked its pathogenic potential to
a modulation of the host immune response [38]. A re-
cent study demonstrates that field strains of EHV-2 were
detected in 50 % of horses tested, and after reactivation
of latent infection using systemic corticosteroids, EHV-2
is detectable in the trachea up to 14 days [15]. Although
this study and others have failed to show associations
between clinical signs or tracheal neutrophils and EHV-
2 [39], or indeed between EHV-2 viral load and poor
performance [40] a recent study showed that inoculation
with equine herpesvirus-2 results in prolonged neutro-
philia in BALF despite resolution of other clinical signs,
suggesting that the gammaherpesviruses may indeed
play a role in the development of airway inflammation in
horses [14]. Unlike HRV, there is far less evidence in hu-
man medicine for the involvement of herpesviruses in
childhood wheeze or indeed development of asthma. Al-
though serologic evidence of cytomegalovirus infection
(a betaherpesvirus) was more prevalent in infants with
asthma-like bronchial symptoms than in age-matched
infants with no wheezing, arguing for cytomegalovirus
infection playing some role in these cases [41], in a dif-
ferent study, having more than one herpesvirus infection
before the age of three was actually inversely associated
with asthma at age seven [42]. In horses, it has been pro-
posed that EHV-2 modifies Il-10 [43], and may thus
affect long-term respiratory responses through modula-
tion of the immune response. On the other hand, as
EHV2 has been shown to establish latency [44], it may
be that the presence of active shedding is secondary to
airway inflammation rather than a cause of airway in-
flammation. It remains to be determined if EHV-2 is one
of the many possible insults that, combined, drive the
equine respiratory phenotype toward IAD.
There was a relatively small number of horses testing
PCR positive for any other viruses, which is likely due,
as with ERAV, to the natural course of disease in com-
parison to the single sampling timeframe of our study.
Equine influenza virus has been shown to be shed in
nasal secretions of immunized horses for an average of
6–8 days after infection [45], while equine herpesvirus-
1\-4 can be shed in nasal secretions for 14–75 days after
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infection [46, 47] and reactivated latent herpes virus in-
fections are common. [48] A recent study showed that
when subclinical viral respiratory disease was detected
on nasal swab, horses had not seroconverted yet. [12].
Therefore, it is not surprising that sampling apparently
healthy, non-febrile horses at a single time point yielded
low numbers of positive PCR identification of respiratory
virus. In fact, when the prevalence of respiratory disease
in horses in New Zealand was surveyed, although EHV-
2 and EHV-4 were among the most common viruses de-
tected upon PCR, these viruses were only detected in
horses with evidence of febrile respiratory illness [49].
Thus, selection bias likely also contributed to low EHV
detection rates because horses that were PCR positive
for a respiratory virus would more likely have a recent
history of fever and malaise, and would have been ex-
cluded from the study. Nonetheless, it is of interest to
clinicians that in a population of horses without history
or clinical signs of current viral infection, 8/38 horses
were shedding virus, and only one of those horses was
in the control group. Further, nasal discharge, which is
commonly seen in horses with viral respiratory infec-
tions, was not positively associated with PCR-positive
virus status or a diagnosis of IAD (Table 1) and only one
of the horses that shed virus had nasal discharge. This is
in accordance with prior conclusions that subclinical in-
fection with respiratory viruses is common among
equine populations [31, 50].
The strong connections that have been established be-
tween respiratory viral infection and asthma in humans
suggest that this may be a good model for understanding
the relationship between similar equine respiratory vi-
ruses, airway inflammation and functional pulmonary
derangements in horses. Recent studies have shown that
there are multiple factors at play in the development of
disease: asthmatics presenting to the emergency room,
for instance, do not have higher viral loads than non-
asthmatics [51], but it may be that a second hit, such as
an environment high in dust mites [52], as well as the
influences of genetics, diet, age, and immune responses
[53], is necessary to precipitate a crisis. Moreover, there
appear to be, as a recent study termed it, a panoply of
‘unique cellular immune factors’ that work in concert
with HRV to result in wheezing and long-term asthma
in children exposed to HRV [53], including a deficiency
of the interferon response due to Th2 polarization in
atopic individuals and a subsequent maladaptive im-
mune response [53]. Likewise, the development of
equine IAD appears to involve multiple different factors,
including environment, in addition to the proposed role
of respiratory viruses [6, 7]. There is emerging, if some-
what conflicting, evidence that some horses with IAD
also have a polarized Th2 response [54], making it
tempting to speculate that a maladaptive immune
response may likewise contribute to the development of
enhanced airway inflammation and hyperresponsiveness
in horses with ERAV or other viral respiratory infection.
A recent review implicates changes in airway biology
which result in initiation and progression of airway re-
modeling, disruption of the epithelial barrier, decreased
ciliary function, and production of growth factors and
metalloproteinases in HRV-associated asthma perturba-
tions [35]. Although both HRV and the similar picorna-
viruses, ERAV and ERBV, are commonly associated only
with relatively mild upper airway symptoms and signs
including pharyngitis, nasal discharge, coughing and
variable fever, both are able to infect the lower airways
as well as the upper airways, causing long-term airway
inflammation and potentially ciliary dysfunction with
loss of clearance [32, 55, 56]. It is logical, therefore, that
HRV causes reduced lung function [57] and AWHR in
humans [58]. Despite the relatively quick clearance of
HRV from the respiratory system, AWHR to methacho-
line persists in children from 5–11 weeks after natural
infection with HRV [55]. Although a recent study in
horses failed to find an overall increase in AWHR in af-
fected ponies, primarily due to pre-existent AWHR in
principal and control animals, nonetheless, individual
animals did have a heightened response to histamine
after infection with ERAV. [32] In our study, chi-square
analysis showed a strong association between elevated
percentages of BALF neutrophils or mast cells and ab-
normal lung function (either AWHR or response to al-
buterol challenge), P < 0.001, and the majority of IAD
horses (>90 %) had evidence of abnormal lung function
on pulmonary function testing. Our study concords with
findings by other workers, where cough was highly asso-
ciated with a diagnosis of IAD [59, 60]. However, due to
our study design excluding horses with abnormal lung
function from the control group, we were unable to look
for associations across the whole population of horses
between PCR or evidence of viral infection and abnor-
malities on lung function. In contrast to previous studies
from our laboratory [1, 2], there was no correlation be-
tween AWHR and BALF cell percentages. This may be a
reflection of our population: previous studies from our
laboratory have had a significant proportion of young
racehorses, whereas this study involved primarily middle-
aged lower-level sport horses.
Clearly, there are limitations to this study. Although
our samples were quickly placed on ice and transferred
within 4 hours to the laboratory for appropriate storage,
it is possible that samples may have degraded in transit.
In addition, we may have had a higher percentage of
horses testing positive on PCR if we had swabbed the
nasopharynx rather than the nasal passages alone [30].
We were unable to use serology to investigate the rela-
tionship between IAD and viruses other than EHV-2,
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ERAV and ERBV, as we sampled only at one time-point,
and we were thus unable to differentiate vaccinal status
vs natural exposure. Had we sampled at 4-week intervals
to detect rising titers, we might have detected a role for
the more commonly diagnosed respiratory viruses in
the development of IAD. As discussed above, it has
been suggested that cumulative exposures to HRV are
critical to the development of the asthmatic pheno-
type [35]. Although a longitudinal study of young
Standardbred racehorses failed to find any associa-
tions among seroconversion, single antibody titers, or
PCR positivity to rhinitis viruses and poor perform-
ance [12], a longitudinal study of respiratory viral dis-
ease in older performance horses may be necessary to
adequately parse out the connection to development
of the IAD phenotype which may develop with time
and repeated insult to the respiratory system. Because
environment is thought to be one of the most im-
portant of the possible repeated insults to the equine
respiratory system, we standardized environment as
much as possible by ensuring that horses came from
very similar environments, namely a combination of
stall and turnout, and that they had similar bedding
and similar feed. We also ensured that control horses
came from multiple different barns, therefore render-
ing the possibility of infection with respiratory virus
more random. Nonetheless, in an ideal experiment,
exposure to respiratory virus would be the only inter-
vention made in horses housed in identical environ-
ments, thus rendering any outcome more obvious and
clear. Moreover, there is a strong heritable component
to asthma in children as well as mutations that may
enhance viral binding in asthmatic airways [61]; no
heritable component has yet been demonstrated for
IAD in horses but there is some evidence for genetics
to play a role in the more severe disease, RAO [62].
Future investigations into the genetics of IAD will be
necessary eventually to determine if genetics and viral
respiratory infection work together to create chronic
disease.
Conclusion
In conclusion, this study found that a greater percentage
of horses with diagnosis of recent onset or exacerbation
of IAD defined by appropriate clinical history, BALF cy-
tology and PFTs had positive titers to ERAV than did
control horses, and horses with a diagnosis of IAD had
higher log-transformed titers to ERAV than controls. In
addition, a diagnosis of IAD was associated with nasal
shedding of EHV-2 (positive nasal swab PCR). The au-
thors recognize that these findings are associations with-
out having evidence of causation; nonetheless, this study
provides an intriguing possible link between viral re-
spiratory disease and exacerbation or onset of IAD. IAD
remains a persistent problem in the equine population
and has strong similarities to the human disease, asthma,
the development or exacerbation of which is strongly as-
sociated with viral respiratory disease. Our study sug-
gests that there is merit in further investigation of the
role of viral respiratory disease in initiation or exacerba-
tion of IAD in order to better understand disease in both
horses and humans.
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